Precigen Inc. Secures FDA Approval for PAPZIMEOS, Offering New Hope to Adult RRP Patients
Reuters
Aug 15
<a href="https://laohu8.com/S/PGEN">Precigen</a> Inc. Secures FDA Approval for PAPZIMEOS, Offering <a href="https://laohu8.com/S/NHPEF">New Hope</a> to Adult RRP Patients
Precigen Inc. has announced the FDA approval of PAPZIMEOS, a groundbreaking therapy for adult patients with Recurrent Respiratory Papillomatosis (RRP). This historic approval marks a significant milestone for the RRP community, offering a new FDA-approved treatment option that has the potential to reduce or eliminate the need for repeated surgeries. The approval was based on data from a pivotal study led by Clint T. Allen, MD, and Scott M. Norberg, DO, at the National Institutes of Health, which successfully met its primary safety and efficacy endpoints. Precigen will begin promoting PAPZIMEOS immediately and has established Papzimeos SUPPORT, a comprehensive patient support program. A conference call will be held on August 18 to provide further details regarding the approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY47895) on August 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.